Presenter Information

Madeleine PetersFollow

Presentation Type

Panel Discussion

Start Date

20-3-2021 11:30 AM

Abstract

Chagas disease, classified as a neglected tropical disease (NTD), is caused by the parasite Trypanosoma cruzi and is an underfunded and under researched disease. The only FDA-approved drug in the United States is benznidazole which is expensive, harmful, and only effective in the illness’ acute phase. The goal is to create a more effective, lower costing and less harmful drug by using a condensation reaction to substitute different amines to diethyl squarate (DES) to make cycloalkylsquaramides. Both DES and the amines used are relatively low in price with a simple, efficient, and high yielding synthesis. Low synthetic cost and ability to puncture the parasites cell membrane causing parasitic death are why cycloalkylsquaramides were chosen. Nuclear magnetic resonance (NMR) spectroscopy showed the desired compounds were made. For future works, the compounds will be sent to the Drugs for Neglected Diseases initiative (DNDi) and tested against the parasite to measure their EC50.

Share

COinS
 
Mar 20th, 11:30 AM

Lowering the cost and raising the efficiency of a cure to Chagas disease

Chagas disease, classified as a neglected tropical disease (NTD), is caused by the parasite Trypanosoma cruzi and is an underfunded and under researched disease. The only FDA-approved drug in the United States is benznidazole which is expensive, harmful, and only effective in the illness’ acute phase. The goal is to create a more effective, lower costing and less harmful drug by using a condensation reaction to substitute different amines to diethyl squarate (DES) to make cycloalkylsquaramides. Both DES and the amines used are relatively low in price with a simple, efficient, and high yielding synthesis. Low synthetic cost and ability to puncture the parasites cell membrane causing parasitic death are why cycloalkylsquaramides were chosen. Nuclear magnetic resonance (NMR) spectroscopy showed the desired compounds were made. For future works, the compounds will be sent to the Drugs for Neglected Diseases initiative (DNDi) and tested against the parasite to measure their EC50.